Quick Answer
Rapport Therapeutics, Inc. reported Net Income of -$111.48 million for fiscal year 2025.
Rapport Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$111.48M | -42.4% |
| 2024 | -$78.31M | -125.1% |
| 2023 | -$34.79M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$26.93M | -53.5% | -0.7% |
| June 30, 2025 | -$26.73M | -47.5% | -11.1% |
| March 31, 2025 | -$24.06M | -6.1% | -37.2% |
| September 30, 2024 | -$17.54M | -101.4% | +3.2% |
| June 30, 2024 | -$18.12M | -182.7% | +20.1% |
| March 31, 2024 | -$22.67M | -268.8% | -160.3% |
| September 30, 2023 | -$8.71M | — | -35.8% |
| June 30, 2023 | -$6.41M | — | -4.3% |
- Rapport Therapeutics, Inc. showed a decrease of -42.4% in Net Income compared to the prior fiscal year.
- Over the 2023–2025 period, Rapport Therapeutics, Inc.’s net income has declined by 220.5% (from -$34.79 million to -$111.48 million).
- The most recent figure is from Rapport Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: